President Trump has exposed the dirty secret of drug pricing: There is a shadowy third player in the transaction between patients and their pharmacists: middlemen who have taken a big kickback from the drug manufacturer, which may or may not be reflected in patients' out-of-pocket costs.
EpiPen is not unique. It falls into a category of old drugs, many of which should have long been subject to generic competition.
The goal of re-importation is to provide American consumers with access to drugs at the world market price - not the inflated price now paid only by Americans.
For all of life's discontents, according to the pharmaceutical industry, there is a drug and you should take it. Then for the side effects of that drug, then there's another drug, and so on. So we're all taking more drugs, and more expensive drugs.
Because Genentech is a leading developer of cancer therapies, some doctors also fear that the company's pricing plans for Avastin - around $8,800 a month - may encourage other companies to charge more for their own oncology drugs.
The rising cost of prescription drugs has sparked a prairie fire that is spreading across our nation.
While American taxes pay for much of the research and development that goes into creating the new, life-saving drugs, American consumers continue to subsidize the cost of the drugs for consumers across the world.
The status quo on prescription drug prices is deeply broken and unsustainable.
I am deeply troubled by Mylan's misclassification of the EpiPen as a generic drug.
How long do we have to keep fighting for affordable prescription drugs?
